An Investigational Study of BG-75202 Alone and in Combination With Other Agents in Patients With Myeloid Malignancies

← catalyst calendar

NCT07619287 · readout in 772 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 1

Status

Recruiting

Study type

Interventional

Design

Non randomized · None · Treatment

Enrollment

118estimated

Sites

Countries

Australia, China, New Zealand

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-06-23

actual

When the study began enrolling

Primary completion

2028-09-30

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-09-30

estimated

The whole study's end, after follow-up

First posted

2026-06-01

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-18

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Myeloid Malignancy

Interventions

Drug: BG-75202
Drug: Hypomethylation Agent (HMA)

Primary outcomes

what the primary-completion date above is the date OF

Part 1a: Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)

measured From first dose to 30 days after last dose or initiation of a new anticancer therapy, whichever occurs first, up to approximately18 months

Phase 1a: Recommended Dose for Expansion (RDFE) of BG-75202

measured Estimated approximately 18 months

Phase 1b: Dose Optimization: Complete Remission (CR) Rate

measured Up to approximately 12 months

Phase 1b: Dose Optimization: Complete Remission (CR) plus CR With Partial Hematologic Recovery (CRh) Rate

measured Up to approximately 12 months

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed